FDA OCE commentary: Cancer burden facing Asian Americans partly caused by racism

FDA cracks down on direct-to-consumer ads, including the Hims & Hers Superbowl blitz

FDA has begun to crack down on direct-to-consumer prescription drug advertising.

September 19, 2025

People across Croatia gain access to advanced radiosurgery close to home at UPMC Hillman Cancer Center in Zabok

UPMC Hillman Cancer Center at Zabok General Hospital in Croatia is expanding access to the most advanced radiosurgery services for people across the country with the introduction of the Varian TrueBeam stereotactic body radiation therapy and stereotactic radiosurgery system. The new system delivers radiosurgery treatment with pinpoint accuracy and image-guided precision in a shorter amount of time than current conventional treatments.

September 19, 2025

Vol.51 No.34

Drugs & Targets

FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer

FDA approved gemcitabine intravesical system (Inlexzo) for adults with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

September 19, 2025

Vol.51 No.34

Drugs & Targets

FDA approves Bosaya and Aukelso, denosumab biosimilars, for osteoporosis

FDA approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) injections, biosimilars of Prolia and Xgeva respectively, for the treatment of osteoporosis. In addition, FDA granted provisional interchangeability designation for both Bosaya and Aukelso.

September 19, 2025

Vol.51 No.34

Drugs & Targets

FDA approves selumetinib for pediatric neurofibromatosis indication

FDA approved selumetinib (Koselugo) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. FDA previously approved selumetinib capsules for pediatric patients 2 years of age and older with NF1 who have symptomatic, inoperable PN.

September 19, 2025

Vol.51 No.34

Drugs & Targets

FDA, Telix agree on NDA resubmission pathway for TLX101-CDx, an investigational agent for glioma imaging

FDA and Telix have reached an agreement regarding resubmission of its New Drug Application for TLX101-CDx (Floretyrosine F18 or 18F-FET, Pixclara), an investigational agent for the imaging of glioma, a rare and life-threatening brain cancer.

September 19, 2025

Vol.51 No.34

FDA OCE commentary: Cancer burden facing Asian Americans partly caused by racism

YOU MAY BE INTERESTED IN

FDA cracks down on direct-to-consumer ads, including the Hims & Hers Superbowl blitz

People across Croatia gain access to advanced radiosurgery close to home at UPMC Hillman Cancer Center in Zabok

FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer

FDA approves Bosaya and Aukelso, denosumab biosimilars, for osteoporosis

FDA approves selumetinib for pediatric neurofibromatosis indication

FDA, Telix agree on NDA resubmission pathway for TLX101-CDx, an investigational agent for glioma imaging

Renew today!

Subscriber content

Never miss an issue!

Login